TG THERAPEUTICS, INC.

Form 8-K March 12, 2014							
UNITED STATES							
SECURITIES AND EXCHANGE COMMISSION							
WASHINGTON, D.C. 20549							
FORM 8-K							
CURRENT REPORT							
Pursuant to Section 13 or	15(d) of the						
Securities Exchange Act of 1934							
Date of report (Date of earliest event reported): March 11, 2014							
TG Therapeutics, Inc.							
(Exact Name of Registrant	as Specified in Charter)						
Delaware	001-32639						
(State or Other Jurisdiction (Commission File Number		36-3898269					
of Incorporation)	(IRS Employer Identification No.)						

3 Columbus Circle, 15th Floor

٦	Jew	Vork	New	Vork	10019
1	16W	I UI K.	INCW	IUIK	10017

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

 $99.1 \frac{\text{Underwriting Agreement between TG Therapeutics, Inc. and Ladenburg Thalmann & Co. Inc., dated March 11, 2014.}$

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.

(Registrant)

Date: March 12, 2014

By:/s/ Sean A. Power Sean A. Power Chief Financial Officer

- 3 -

INDEX TO EXHIBITS

Exhibit

Number Description

99.1 Underwriting Agreement between TG Therapeutics, Inc. and Ladenburg Thalmann & Co. Inc., dated March 11, 2014.

- 4 -